Business Wire07.10.18
EndoClot Plus Inc., a privately held medical device company founded by surgeons and biomaterial scientists, announces the CE approval of EndoClot Adhesive manufactured by EndoClot Plus Co. Ltd. located in Suzhou, China.
EndoClot Adhesive is a single-use kit that consists of Adhesive Hemostatic Polymer (AHP) and a unique applicator system to ensure accurate delivery of the hemostatic powder to the lesion within the GI tract. AHP particles are hydrophilic and instantly create a gel barrier when in contact with blood or GI fluids. AHP particles are also very adhesive to assist in maintaining the clot formation as well as sealing and protecting the wound over several days.
“The adhesiveness and long-lasting properties of EndoClot Adhesive make it an ideal solution for bleeding control and the reduction of post procedure re-bleeding,” said James Ji, founder of EndoClot Plus. “The wound protection offered by EndoClot Adhesive following ESD and EMR procedures will delight endoscopists who have been asking us to develop such a product.”
The introduction of EndoClot Adhesive has begun in Europe and other selected international markets. EndoClot Plus will utilize its established network of distribution partners along with new strategic partners to bring this innovative product to the GI Endoscopy market.
EndoClot Plus is focused on utilizing its expertise to develop customized medical devices to meet clinical needs. With its vision and technology, EndoClot Plus aims to become the leading company in creating new biomaterial therapeutic solutions for GI Endoscopy.
EndoClot Plus Inc. (EPI) is a privately owned company in Santa Clara, Calif. In collaboration with surgeons and biomaterial scientists, EPI developed a breakthrough technology to control bleeding in the gastrointestinal tract by spraying a unique and proprietary powder directly to the wound during endoscopy. The EndoClot Polysaccharide Hemostatic System (EndoClot PHS) is currently being sold outside the United States in selected international markets. The mission of EndoClot Plus is to provide new therapeutic solutions to the world market for GI Endoscopy.
EndoClot Adhesive is a single-use kit that consists of Adhesive Hemostatic Polymer (AHP) and a unique applicator system to ensure accurate delivery of the hemostatic powder to the lesion within the GI tract. AHP particles are hydrophilic and instantly create a gel barrier when in contact with blood or GI fluids. AHP particles are also very adhesive to assist in maintaining the clot formation as well as sealing and protecting the wound over several days.
“The adhesiveness and long-lasting properties of EndoClot Adhesive make it an ideal solution for bleeding control and the reduction of post procedure re-bleeding,” said James Ji, founder of EndoClot Plus. “The wound protection offered by EndoClot Adhesive following ESD and EMR procedures will delight endoscopists who have been asking us to develop such a product.”
The introduction of EndoClot Adhesive has begun in Europe and other selected international markets. EndoClot Plus will utilize its established network of distribution partners along with new strategic partners to bring this innovative product to the GI Endoscopy market.
EndoClot Plus is focused on utilizing its expertise to develop customized medical devices to meet clinical needs. With its vision and technology, EndoClot Plus aims to become the leading company in creating new biomaterial therapeutic solutions for GI Endoscopy.
EndoClot Plus Inc. (EPI) is a privately owned company in Santa Clara, Calif. In collaboration with surgeons and biomaterial scientists, EPI developed a breakthrough technology to control bleeding in the gastrointestinal tract by spraying a unique and proprietary powder directly to the wound during endoscopy. The EndoClot Polysaccharide Hemostatic System (EndoClot PHS) is currently being sold outside the United States in selected international markets. The mission of EndoClot Plus is to provide new therapeutic solutions to the world market for GI Endoscopy.
